
News|Articles|June 22, 2026
Faricimab (Vabysmo® , Roche Products Ltd) for visual impairment due to macular oedema secondary to retinal vein occlusion: An educational supplement
This is a promotional supplement commissioned by Roche Products Limited.
Advertisement
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
SubscribeAdvertisement
Latest CME
Advertisement
Advertisement
Trending on Eye Care Network - Ophthalmology Times
1
Port Delivery System Therapies in Retinal Vascular Diseases
2
Offline smartphone AI accurately detects DR, glaucoma, and AMD in real-world study
3
FDA grants RMAT designation to Emmecell's EO2002 for corneal endothelial disease
4
NeuroOp Guru: What a big data study reveals about NAION and stroke risk
5


















